UNSPSC 51171933: Colloidal bismuth subcitrate

This classification denotes a cytoprotective agent and anti-ulcer agent with the molecular formula 2C6H5O7.Bi.3K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HS813P8QPX, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, bismuth(3+) potassium salt (2:1:3) but generally known as bismuth subcitrate, which bears US NIH Compound Identifier 6335486. European Medicines Agency schedules Bismuth subcitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13089MIG.

World Health Organization schedules bismuth subcitrate in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3].

UNSPSC 51171933 Colloidal bismuth subcitrate is a Commodity code that nominally addresses a specific pharmaceutical ingredient, but the recent state and local opportunities tagged under it reflect broader pharmaceutical and drug-testing procurement activity unrelated to bismuth subcitrate itself. The code shows limited direct relevance to actual buying patterns in state and local government procurement; the recent opportunities instead center on drug-testing specimen collection services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution contracts through cooperative purchasing vehicles.

The issuing bodies include Collin County Community Supervision and Corrections Department (Texas), the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving participating state and local agencies across multiple states including Oregon. Representative recent activity includes Collin County's RFP 2026-327 for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 over two years with optional renewals; Texas HHS's RFI HHS0017013 (posted March 27, 2026, responses due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with contract effectiveness July 1, 2026. Activity is concentrated in Texas and the Upper Midwest, though the MMCAP vehicle spans participating jurisdictions across multiple states. The mismatch between the code's nominal scope (colloidal bismuth subcitrate, a gastrointestinal medication ingredient) and the actual procurement focus (drug-testing operations, prescription fulfillment intermediation, and generic pharmaceutical distribution) suggests this code may be a tagging error in one or more of these solicitations and does not represent meaningful commercial opportunity under the code's intended pharmaceutical-ingredient definition.